Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
Stem Cells Dev. 2011 May;20(5):795-807. doi: 10.1089/scd.2010.0343. Epub 2011 Feb 1.
Induced pluripotent stem (iPS) cells have great potential for regenerative medicine and gene therapy. Thus far, iPS cells have typically been generated using integrating viral vectors expressing various reprogramming transcription factors; nonintegrating methods have been less effective and efficient. Because there is a significant risk of malignant transformation and cancer involved with the use of iPS cells, careful evaluation of transplanted iPS cells will be necessary in small and large animal studies before clinical application. Here, we have generated and characterized nonhuman primate iPS cells with the goal of evaluating iPS cell transplantation in a clinically relevant large animal model. We developed stable Phoenix-RD114-based packaging cell lines that produce OCT4, SOX2, c-MYC, and KLF4 (OSCK) expressing gammaretroviral vectors. Using these vectors in combination with small molecules, we were able to efficiently and reproducibly generate nonhuman primate iPS cells from pigtailed macaques (Macaca nemestrina). The established nonhuman primate iPS cells exhibited pluripotency and extensive self-renewal capacity. The facile and reproducible generation of nonhuman primate iPS cells using defined producer cells as a source of individual reprogramming factors should provide an important resource to optimize and evaluate iPS cell technology for studies involving stem cell biology and regenerative medicine.
诱导多能干细胞(iPS 细胞)在再生医学和基因治疗方面具有巨大的潜力。到目前为止,iPS 细胞通常是通过表达各种重编程转录因子的整合病毒载体来生成的;非整合方法的效果和效率较低。由于使用 iPS 细胞存在恶性转化和癌症的重大风险,因此在临床应用之前,在小动物和大动物研究中需要对移植的 iPS 细胞进行仔细评估。在这里,我们生成并表征了非人类灵长类动物 iPS 细胞,目的是在临床相关的大动物模型中评估 iPS 细胞移植。我们开发了稳定的 Phoenix-RD114 为基础的包装细胞系,能够产生 OCT4、SOX2、c-MYC 和 KLF4(OSCK)表达的γ逆转录病毒载体。我们使用这些载体与小分子相结合,能够高效且可重复地从猪尾猕猴(Macaca nemestrina)中生成非人类灵长类动物 iPS 细胞。所建立的非人类灵长类动物 iPS 细胞表现出多能性和广泛的自我更新能力。使用定义明确的生产细胞作为单个重编程因子的来源,简便且可重复地生成非人类灵长类动物 iPS 细胞,应该为优化和评估 iPS 细胞技术提供重要资源,这些技术涉及干细胞生物学和再生医学。